Nurix Therapeutics, Inc. Common stock (NRIX) Financials
Key financial figures for Nurix Therapeutics, Inc. Common stock (Q3 2026).
Nurix Therapeutics, Inc. reported revenue of $673.1 million for Q3 FY2026, up 8426.3% from the same period a year earlier. Net income was $549.8 million, or $4.73 per share. Operating margin came to 83.12%, against -1157.65% a year earlier. Free cash flow for the period was $614.2 million. Across the last 5 reported quarters, quarterly revenue has risen from $7.9 million in Q3 FY2025 to $673.1 million in Q3 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Nurix Therapeutics, Inc. are on the SentiSense financials page.
- Revenue
- $673M
- Net Income
- $550M
- EPS
- $4.93
- Total Assets
- $1.2B
- Operating Cash Flow
- $616M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $673M | $550M | $4.73 | 83.12% | $614M |
| Q2 FY2026 | $9M | -$90M | -$0.81 | -1041.73% | -$99M |
| Q1 FY2026 | $6M | -$87M | -$0.79 | -1479.45% | -$73M |
| Q4 FY2025 | $14M | -$78M | -$0.82 | -612.03% | -$73M |
| Q3 FY2025 | $8M | -$86M | -$1.03 | -1157.65% | -$60M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $84M | -$264M | -$3.05 | -340.16% | -$263M |
| FY2024 | $55M | -$194M | -$2.88 | -390.52% | -$182M |
| FY2023 | $77M | -$144M | -$2.65 | -201.41% | -$90M |
Frequently asked questions
What was Nurix Therapeutics, Inc.'s revenue last quarter?
Nurix Therapeutics, Inc. reported revenue of $673.1 million for Q3 FY2026, up 8426.3% from the same period a year earlier.
Is Nurix Therapeutics, Inc. profitable?
Yes. Nurix Therapeutics, Inc. reported net income of $549.8 million for Q3 FY2026, a net margin of 81.69% on revenue.
How has Nurix Therapeutics, Inc.'s margin trended?
Operating margin was 83.12% in Q3 FY2026, compared with -1157.65% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Nurix Therapeutics, Inc. generate?
Nurix Therapeutics, Inc. generated free cash flow of $614.2 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Nurix Therapeutics, Inc. Common stock on SentiSense, with up to forty quarters and twenty fiscal years of history.